Scientists at Agios Pharmaceuticals have shown that a mutated metabolic enzyme common to many brain cancers acts like an oncogene, reversing the previously held belief that it was not involved in cancer-causing activity. They also linked the mutation, IDH1, to a potential predictive biomarker for glioma patients. Their work helps validate a drug discovery apporach based on the study of proliferating cancer cell metabolism.
Mark L. Ratner
Scientists at Agios Pharmaceuticals Inc. have shown that a mutated form of a metabolic enzyme common to many brain...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
CSO Jacob Thyssen tells Scrip that the monoclonal antibody which blocks the IL-22RA1 receptor subunit is a very safe and effective option to treat the chronic inflammatory skin disease.
With patent expiry for its blockbuster blood cancer drug Jakafi on the horizon, Incyte will need to translate these povorcitinib wins from clinic to market.
Shortlists of potential winners in all categories of the Citeline Japan Awards 2025 have now been released. Join us at the event in Tokyo on October 21, it’s not too late to book your table!
The company announced positive Phase III data for the drug in fibrodysplasia ossificans progressiva, as well as Phase II combination data among patients with obesity.
Shortlists of potential winners in all categories of the Citeline Japan Awards 2025 have now been released. Join us at the event in Tokyo on October 21, it’s not too late to book your table!
Plus deals involving Adagene/Exelixis, Biocytogen/Tubulis, Kwangdong/Ocugen, Dr. Reddy’s/J&J, Zydus/Synthon, Stallergenes/Nuance, Argo/Novartis, XW Pharma/Avadel, Biocytogen/Merck & Co., JCR/Medipal, Novatim/Radiance and more.
The company announced positive Phase III data for the drug in fibrodysplasia ossificans progressiva, as well as Phase II combination data among patients with obesity.
